The spectrum of latent tuberculosis: rethinking the goals of prophylaxis

By C. Barry, H. Boshoff, V. Dartois, T. Dick, S. Ehrt, J. Flynn, D. Schnappinger, R. Wilkinson, D. Young. Nature Reviews Microbiology, 2009

1,387 citations recorded by the source corpus.

Immunological tests provide evidence of latent tuberculosis in one third of the global population, which corresponds to more than two billion individuals. Latent tuberculosis is defined by the absence of clinical symptoms but carries a risk of subsequent progression to clinical disease, particularly in the context of co-infection with HIV. In this Review we discuss the biology of latent tuberculosis as part of a broad range of responses that occur following infection with Mycobacterium tuberculosis, which result in the formation of physiologically distinct granulomatous lesions that provide microenvironments with differential ability to support or suppress the persistence of viable bacteria. We then show how this model can be used to develop a rational programme to discover effective drugs for the eradication of M. tuberculosis infection.

Subfields: Epidemiology, Infectious Diseases, Surgery

View Paper: https://www.semanticscholar.org/paper/bfc9d4eb0f3b19234c13b3c15c95550bda80807b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. M. Gengenbacher
2. A. O’Garra
3. Madhukar Pai
4. Stefan H. E. Kaufmann
5. R. Wilkinson
6. A. Zwerling
7. M. Berry
8. Finlay W Mcnab

In Infectious Diseases

1. M. Gengenbacher
2. A. O’Garra
3. Madhukar Pai
4. Stefan H. E. Kaufmann
5. R. Wilkinson
6. A. Zwerling
7. M. Berry
8. Finlay W Mcnab

In Surgery

1. A. O’Garra
2. Madhukar Pai
3. Stefan H. E. Kaufmann
4. R. Wilkinson
5. M. Gengenbacher
6. A. Zwerling
7. M. Berry
8. Finlay W Mcnab

Citations in the corpus

• The challenge of new drug discovery for tuberculosis (2011, background): “To achieve global control of this epidemic, there is an urgent need for new TB drugs, which can: (1) shorten treatment duration; (2) target MDR or XDR strains; (3) simplify treatment by reducing the daily pill burden; (4) lower dosing frequency (for example, a once-weekly regimen); and (5) be co-adm”
• Genomic mapping of cAMP receptor protein (CRPMt) in Mycobacterium tuberculosis: relation to transcriptional start sites and the role of CRPMt as a transcription factor (2014, background): “The success of Mycobacterium tuberculosis as one of the most deadly human pathogens depends on its ability to adapt to diverse intracellular and extracellular environments encountered during infection, persistence and transmission [reviewed in (1)].”
• Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection (2014, background): “1) (2, 3), persons with latent TB infection (LTBI) are classically considered to be asymptomatic and not infectious.”
• Mycobacterium tuberculosis: Success through dormancy (2012, background): “How- ever, the risk of active disease is increased in immunocompromising situations such as during antitumor necrosis factor therapy of patients with chronic inflammatory diseases, by diabetes/obesity or by co-infection with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS”
• The immune response in tuberculosis. (2013, background): “The heterogeneity within the latent TB population is gaining more widespread acceptance (18) and highlights the need for diagnostic tools that differentiate the full spectrum of these diverse responses to infection (18, 49, 68).”